
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7472993/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of Serum High–Molecular Weight (HMW) Adiponectin With Total Adiponectin Concentrations in Type 2 Diabetic Patients With Coronary Artery Disease Using a Novel Enzyme-Linked Immunosorbent Assay to Detect HMW Adiponectin. Diabetes, 2006, 55, 1954-1960.	0.6	244
2	Evaluation of the effects of dapagliflozin, a sodiumâ€glucose coâ€transporterâ€2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and nonâ€alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2019, 21, 285-292.	4.4	243
3	Retinol Binding Protein-4 Levels and Clinical Features of Type 2 Diabetes Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2712-2719.	3.6	183
4	Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetology and Metabolic Syndrome, 2016, 8, 45.	2.7	154
5	Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Frontiers in Bioscience - Landmark, 2007, 12, 2957.	3.0	122
6	High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2005, 54, 345-350.	3.4	115
7	High Molecular Weight Adiponectin as a Predictor of Long-Term Clinical Outcome in Patients With Coronary Artery Disease. American Journal of Cardiology, 2007, 100, 569-574.	1.6	113
8	Relationships of Plasma Interleukin-18 Concentrations to Hyperhomocysteinemia and Carotid Intimal-Media Wall Thickness in Patients With Type 2 Diabetes. Diabetes Care, 2003, 26, 2622-2627.	8.6	101
9	Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis, 2017, 261, 44-51.	0.8	75
10	Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Translational Research, 2012, 159, 25-31.	5.0	70
11	Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes. Diabetes Care, 2005, 28, 2211-2216.	8.6	69
12	The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 5237.	4.1	68
13	PPARÂ Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes. Diabetes, 2007, 56, 1662-1670.	0.6	65
14	Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidaseâ€4 in patients with type 2 diabetes and nonâ€alcoholic fatty liver disease. International Journal of Clinical Practice, 2019, 73, e13335.	1.7	61
15	Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1. Metabolism: Clinical and Experimental, 2002, 51, 471-476.	3.4	60
16	Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clinica Chimica Acta, 2004, 348, 139-145.	1.1	60
17	Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabetes Care, 2016, 39, e22-e23.	8.6	48
18	Adiponectin Concentrations in Sera From Patients With Type 2 Diabetes Are Negatively Associated With Sympathovagal Balance as Evaluated by Power Spectral Analysis of Heart Rate Variation. Diabetes Care, 2004, 27, 2392-2397.	8.6	47

#	Article	IF	CITATIONS
19	Elevated Pregnancy-Associated Plasma Protein-A in Sera from Type 2 Diabetic Patients with Hypercholesterolemia: Associations with Carotid Atherosclerosis and Toe-Brachial Index. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5713-5717.	3.6	43
20	Impact of sex, fat distribution and initial body weight on oxytocin's body weight regulation. Scientific Reports, 2017, 7, 8599.	3.3	40
21	High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism: Clinical and Experimental, 2006, 55, 1014-1021.	3.4	37
22	Relation between serum high molecular weight adiponectin and serum ferritin or prohepcidin in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2010, 90, 250-255.	2.8	37
23	Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2015, 110, 250-256.	2.8	35
24	Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Therapy, 2017, 8, 821-827.	2.5	35
25	Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. Clinica Chimica Acta, 2000, 301, 135-145.	1.1	32
26	Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control study. Cardiovascular Diabetology, 2016, 15, 76.	6.8	32
27	Results of Blood Inflammatory Markers Are Associated More Strongly With Toe-Brachial Index Than With Ankle-Brachial Index in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 1381-1386.	8.6	29
28	Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. Translational Research, 2009, 154, 175-182.	5.0	29
29	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes. Endocrine, 2015, 50, 659-664.	2.3	29
30	Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Research and Clinical Practice, 2009, 85, 147-152.	2.8	26
31	Effects of retinol binding protein-4 on vascular endothelial cells. Biochemical and Biophysical Research Communications, 2011, 408, 58-64.	2.1	25
32	Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy. Diabetes Technology and Therapeutics, 2014, 16, 840-845.	4.4	25
33	Cardiovascular Disease in Patients with Diabetic Nephropathy. Current Molecular Medicine, 2008, 8, 533-543.	1.3	24
34	Effects of Rosuvastatin and Colestimide on Metabolic Parameters and Urinary Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients with Hyperlipidemia. Southern Medical Journal, 2009, 102, 361-368.	0.7	24
35	The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Translational Research, 2013, 162, 309-316.	5.0	24
36	Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naÃ⁻ve Japanese patients with type 2 diabetes: l'D GOT trial. Diabetes Research and Clinical Practice, 2017, 130, 237-243.	2.8	24

#	Article	IF	CITATIONS
37	Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: Possible application as a marker for vascular endothelial injury. Metabolism: Clinical and Experimental, 1998, 47, 362-365.	3.4	23
38	Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis. Journal of Diabetes and Its Complications, 2020, 34, 107703.	2.3	23
39	Effects of losartan on serum total and high–molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. Metabolism: Clinical and Experimental, 2008, 57, 1278-1285.	3.4	20
40	Parathyroid Carcinoma with Metastatic Calcification Identified by Technetium-99m Methylene Diphosphonate Scintigraphy Internal Medicine, 1996, 35, 392-395.	0.7	18
41	Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy. Translational Research, 2004, 144, 92-99.	2.3	18
42	Serum high–molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus. Metabolism: Clinical and Experimental, 2009, 58, 1470-1476.	3.4	18
43	Bezafibrate, a peroxisome proliferator–activated receptor α agonist, decreases circulating CD14+CD16+ monocytes in patients with type 2 diabetes. Translational Research, 2015, 165, 336-345.	5.0	18
44	Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. International Journal of Cardiology, 2021, 331, 243-248.	1.7	18
45	Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. Diabetes Research and Clinical Practice, 2017, 133, 10-12.	2.8	16
46	High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism: Clinical and Experimental, 2003, 52, 1517-1522.	3.4	15
47	High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes. Translational Research, 2009, 153, 199-203.	5.0	15
48	Determinants of Serum High Molecular Weight (HMW) Adiponectin Levels in Patients with Coronary Artery Disease: Associations with Cardio-renal-anemia Syndrome. Internal Medicine, 2011, 50, 2953-2960.	0.7	15
49	Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: Effects of short-term improved glycemic control and adiponectin. Translational Research, 2012, 159, 15-24.	5.0	15
50	Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study. Endocrine Journal, 2018, 65, 101-111.	1.6	13
51	Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. European Journal of Endocrinology, 2020, 183, K7-K12.	3.7	13
52	Profound Reduction in T-helper (Th) 1 lymphocytes in Peripheral Blood from Patients with Concurrent Type 1 Diabetes and Graves' Disease. Endocrine Journal, 2006, 53, 377-385.	1.6	11
53	The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. Expert Opinion on Pharmacotherapy, 2017, 18, 743-751.	1.8	11
54	Synergistic Association of Metabolic Syndrome and Overt Nephropathy With Elevated Asymmetric Dimethylarginine in Serum and Impaired Cutaneous Microvasodilation in Patients With Type 2 Diabetes. Diabetes Care, 2006, 29, 928-930.	8.6	10

#	Article	IF	CITATIONS
55	Role of retinol-binding protein 4 in the pathogenesis of Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2008, 3, 161-173.	2.4	8
56	Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. Journal of Diabetes and Its Complications, 2021, 35, 107885.	2.3	7
57	No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan. American Journal of the Medical Sciences, 2021, 362, 104-105.	1.1	7
58	Stiff-Man Syndrome Associated with Antecedent Myasthenia Gravis and Organ-Specific Autoimmunopathy Internal Medicine, 1997, 36, 308-311.	0.7	6
59	Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. Journal of Medical Case Reports, 2019, 13, 99.	0.8	6
60	Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes. American Journal of the Medical Sciences, 2020, 360, 261-267.	1.1	6
61	Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Future Lipidology, 2006, 1, 429-440.	0.5	5
62	CDâ€l <i>^{db/db}</i> mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis. Journal of Diabetes Investigation, 2020, 11, 1470-1481.	2.4	5
63	Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya Journal of Medical Science, 2017, 79, 9-16.	0.3	5
64	Macrophageâ€specific hypoxiaâ€inducible factorâ€1α deletion suppresses the development of liver tumors in highâ€fat dietâ€fed obese and diabetic mice. Journal of Diabetes Investigation, 2019, 10, 1411-1418.	2.4	4
65	Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) coâ€formulation therapy twiceâ€daily with free combination of GLPâ€1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial. International Journal of Clinical Practice, 2021, 75, e13734.	1.7	4
66	Intensive risk factor management and cardiovascular autonomic neuropathy in typeÂ2 diabetes in the Action to Control Cardiovascular Risk in Diabetes trial: A postâ€hoc analysis. Journal of Diabetes Investigation, 2021, 12, 1316-1318.	2.4	4
67	Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease. Journal of Investigative Medicine, 2021, 69, 1324-1329.	1.6	4
68	Updates in diabetic neuropathy: A call for new diagnostic and treatment approaches. Journal of Diabetes Investigation, 2022, 13, 432-434.	2.4	4
69	Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings. Diabetology International, 2015, 6, 26-32.	1.4	3
70	Concurrent variant type 3 autoimmune polyglandular syndrome and pulmonary arterial hypertension in a Japanese woman. Endocrine Journal, 2018, 65, 493-498.	1.6	3
71	Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. Endocrine Journal, 2022, 69, 941-945.	1.6	3
72	Author reply. Translational Research, 2012, 160, 164.	5.0	2

#	Article	IF	CITATIONS
73	Bullous pemphigoid associated with dipeptidyl peptidaseâ€4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication. Clinical Case Reports (discontinued), 2020, 8, 2007-2012.	0.5	2
74	Acute effect of addâ€on therapy with tofogliflozin, a sodium glucose coâ€transporter 2 inhibitor, on 24â€hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidaseâ€4 inhibitors. International Journal of Clinical Practice, 2021, 75, e14732.	1.7	2
75	Epalrestat induces cell proliferation and migration in endothelial cells via mTOR activation through PI3/Akt signaling. Diabetology International, 2014, 5, 105-111.	1.4	1
76	Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study. Diabetology International, 2016, 7, 25-33.	1.4	1
77	Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study. Diabetes Therapy, 2017, 8, 445-449.	2.5	1
78	Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomy. Endocrine Journal, 2021, 68, 1187-1195.	1.6	1
79	Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity. Internal Medicine, 2022, , .	0.7	0
80	Effects of treatment with methimazole on circulating CD4 ⁺ and CD8 ⁺ TÂcells positive for programed cell death proteinâ€1 and on subsets of CD4 ⁺ TÂcells in untreated hyperthyroid patients with Graves' disease. Clinical Endocrinology, 0, , .	2.4	0
81	Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes. IJC Heart and Vasculature, 2022, 41, 101071.	1.1	0